Posted by Michael Wonder on 23 Nov 2023
European Commission approves Kaftrio in combination with ivacaftor for the treatment of children with cystic fibrosis ages 2 through 5
23 November 2023 - More than 1,200 children are newly eligible for a medicine that could treat the underlying cause of their disease.
Vertex Pharmaceuticals today announced that the European Commission has granted approval for the label expansion of Kaftrio (ivacaftor/tezacaftor/elexacaftor) in a combination regimen with ivacaftor for the treatment of children with cystic fibrosis ages 2 through 5 years old who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator gene.
